Meeting
2021 ASCO Annual Meeting
Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2+ breast leptomeningeal disease.
Authors
Kamran A. Ahmed
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Kamran A. Ahmed , Youngchul Kim , Michelle DeJesus , Priya Kumthekar , Nicole Olivia Williams , Joshua David Palmer , Pierre Giglio , Adrienne Ann Boire , John Arrington , Solmaz Sahebjam , Marilin Rosa , Hatem Hussein Soliman , Hsiang-Hsuan Michael Yu , Hyo S. Han , Peter A. J. Forsyth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT04588545
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS1099)
DOI
10.1200/JCO.2021.39.15_suppl.TPS1099
Abstract #
TPS1099
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Efficacy of intrathecal delivery of peptide-pulsed type 1 conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models.
First Author: Vincent Law
Poster
2023 ASCO Annual Meeting
Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).
First Author: Isabella Claudia Glitza
Poster
2021 ASCO Annual Meeting
Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
First Author: Ida John
Poster
2021 ASCO Annual Meeting
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
First Author: Giuseppe Curigliano